Cargando…

Molecular signature associated with cladribine treatment in patients with multiple sclerosis

INTRODUCTION: Little is known about the molecular profiling associated with the effect of cladribine in patients with multiple sclerosis (MS). Here, we aimed first to characterize the transcriptomic and proteomic profiles induced by cladribine in blood cells, and second to identify potential treatme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fissolo, Nicolas, Calvo-Barreiro, Laura, Eixarch, Herena, Boschert, Ursula, Villar, Luisa M., Costa-Frossard, Lucienne, Ferrer, Mireia, Sanchez, Alex, Borràs, Eva, Sabidó, Eduard, Espejo, Carmen, Montalban, Xavier, Comabella, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408299/ https://www.ncbi.nlm.nih.gov/pubmed/37559720 http://dx.doi.org/10.3389/fimmu.2023.1233546

Ejemplares similares

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis
por: Comabella, Manuel, et al.
Publicado: (2021)

Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non‐cell‐autonomous neuronal damage
por: Matute‐Blanch, Clara, et al.
Publicado: (2022)

Therapeutic Effect of IL-21 Blockage by Gene Therapy in Experimental Autoimmune Encephalomyelitis
por: Edo, Ángel, et al.
Publicado: (2022)

Validation of semaphorin 7A and ala-β-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis
por: Cantó, Ester, et al.
Publicado: (2014)

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis
por: Calvo-Barreiro, Laura, et al.
Publicado: (2020)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Regulatory Lymphocytes Are Key Factors in MHC-Independent Resistance to EAE
por: Marín, Nieves, et al.
Publicado: (2014)

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Hsp70 Regulates Immune Response in Experimental Autoimmune Encephalomyelitis
por: Mansilla, M. José, et al.
Publicado: (2014)

Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis
por: Calvo-Barreiro, Laura, et al.
Publicado: (2021)

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
por: Malhotra, Sunny, et al.
Publicado: (2018)

Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
por: Schmierer, Klaus, et al.
Publicado: (2022)

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2015)

A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells
por: Gil-Varea, Elia, et al.
Publicado: (2020)

Treatment with MOG-DNA vaccines induces CD4(+)CD25(+)FoxP3(+) regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
por: Fissolo, Nicolás, et al.
Publicado: (2012)

Metabolomic signatures associated with disease severity in multiple sclerosis
por: Villoslada, Pablo, et al.
Publicado: (2017)

CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
por: Kalatskaya, Irina, et al.
Publicado: (2023)

Different Susceptibility of T and B Cells to Cladribine Depends On Their Levels of Deoxycytidine Kinase Activity Linked to Activation Status
por: Carlini, Federico, et al.
Publicado: (2021)

Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
por: Domínguez-Mozo, María Inmaculada, et al.
Publicado: (2023)

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety
por: Giovannoni, Gavin, et al.
Publicado: (2020)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor
por: Miralles, Marta, et al.
Publicado: (2017)

Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy
por: Wiendl, Heinz, et al.
Publicado: (2022)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2011)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

Neurofilament light chain level is a weak risk factor for the development of MS
por: Arrambide, Georgina, et al.
Publicado: (2016)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
por: Camacho-Toledano, Celia, et al.
Publicado: (2022)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_n14seqqmk8hnq5td4ssjmium8k